No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GYRE Gyre Therapeutics
- 13.420
- +0.810+6.42%
Close Jul 12 16:00 ET
- 13.010
- -0.410-3.06%
Post 17:26 ET
1.15BMarket Cap-13079P/E (TTM)
13.500High12.635Low50.92KVolume12.740Open12.610Pre Close668.24KTurnover0.32%Turnover RatioLossP/E (Static)85.51MShares30.40052wk High20.27P/B210.95MFloat Cap4.80052wk Low--Dividend TTM15.72MShs Float5798.166Historical High--Div YieldTTM6.86%Amplitude0.854Historical Low13.123Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
Express News | Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia
Gyre Therapeutics Low Blood Platelet Treatment Approved in China
Gyre Therapeutics (GYRE) said Tuesday it has received approval in China for avatrombopag maleate tablets for the treatment of low blood platelet count associated with chronic liver disease. The drug i
Express News | Gyre Therapeutics Reports China's NMPA Approval Of Avatrombopag Maleate Tablets For Treatment Of CLD-Associated Thrombocytopenia
Express News | Gyre Therapeutics Announces China’s Nmpa Approval of Avatrombopag Maleate Tablets for the Treatment of Cld-Associated Thrombocytopenia
Comments
$Gyre Therapeutics(GYRE.US$
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...
1
$Gyre Therapeutics(GYRE.US$Gyre Therapeutics Expects Addition To Russell - moomoo
RECAP
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average(.DJI.US$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index(.SPX.US$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index(.IXIC.US$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average(.DJI.US$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index(.SPX.US$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index(.IXIC.US$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
28
3
After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were $Spyre Therapeutics(SYRE.US$, up 26% Monday morning, and $Gyre Therapeutics(GYRE.US$ +10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks(DNA.US$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks(DNA.US$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
4
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg